- Home
- UNCY vs CATO Comparison
UNCY vs CATO Comparison
Compare UNCY & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CATO
- Stock Information
- Founded
- UNCY 2016
- CATO 1946
- Country
- UNCY United States
- CATO United States
- Employees
- UNCY N/A
- CATO N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CATO Clothing/Shoe/Accessory Stores
- Sector
- UNCY Health Care
- CATO Consumer Discretionary
- Exchange
- UNCY Nasdaq
- CATO Nasdaq
- Market Cap
- UNCY 56.4M
- CATO 57.6M
- IPO Year
- UNCY 2021
- CATO N/A
- Fundamental
- Price
- UNCY $4.70
- CATO $2.82
- Analyst Decision
- UNCY Strong Buy
- CATO
- Analyst Count
- UNCY 4
- CATO 0
- Target Price
- UNCY $63.75
- CATO N/A
- AVG Volume (30 Days)
- UNCY 384.1K
- CATO 38.4K
- Earning Date
- UNCY 08-14-2025
- CATO 08-25-2025
- Dividend Yield
- UNCY N/A
- CATO 6.03%
- EPS Growth
- UNCY N/A
- CATO N/A
- EPS
- UNCY N/A
- CATO N/A
- Revenue
- UNCY N/A
- CATO $642,949,000.00
- Revenue This Year
- UNCY N/A
- CATO N/A
- Revenue Next Year
- UNCY $1,178.98
- CATO N/A
- P/E Ratio
- UNCY N/A
- CATO N/A
- Revenue Growth
- UNCY N/A
- CATO N/A
- 52 Week Low
- UNCY $2.75
- CATO $2.19
- 52 Week High
- UNCY $11.00
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- UNCY 52.02
- CATO 46.81
- Support Level
- UNCY $3.97
- CATO $2.77
- Resistance Level
- UNCY $4.43
- CATO $2.95
- Average True Range (ATR)
- UNCY 0.25
- CATO 0.20
- MACD
- UNCY 0.10
- CATO -0.01
- Stochastic Oscillator
- UNCY 73.00
- CATO 19.23
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.